Our Investors

Transport Pharmaceuticals, Inc. is a clinical stage, privately held Delaware Corporation and leader in the convergence of drugs and medical devices for the topical treatment of dermatological conditions. Transport’s late stage lead product, SoloVir™ ETS, represents a potential breakthrough for the treatment of herpes labialis (cold sores), a market with large, unmet medical needs.
Learn More

Partner Opportunities

Transport is an innovative specialty pharmaceutical company, with a dermal product pipeline. Our business model is predicated on integrating commercial partnerships to enhance the value of the large markets we address. We welcome expressions of interest from companies contemplating a partnership with Transport on our clinical-stage opportunities.
Learn More

News & Updates

02.23.09
Transport Pharmaceutical's ETS Terbinafine Phase 1clinical trial data shows a single iontophoretic administration of terbinafine provides a safe method for rapid delivery of high concentrations of drug into the toenail with no systemic exposure.
Learn More

11.18.08
Transport Pharmaceutical's proprietary ETS Terbinafine and ETS Cortisteroid Presented at the 2008 American Association of Pharmaceutical Scientists Annual Meeting in Atlanta, Georgia on November 18, 2008.
Learn More